Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jul 2022

Shao X M, Huang J, Niknafs N, Balan A, Cherry C, White J, Velculescu V E, Anagnostou V, Karchin R

Abstract excerpt

BACKGROUND: Whereas human leukocyte antigen (HLA) class I mutation-associated neoantigen burden has been linked with response to immune checkpoint blockade (ICB), the role of HLA class II-restricted neoantigens in clinical responses to ICB is less studied. We used computational approaches to assess HLA class II immunogenic mutation (IMM) burden in patients with melanoma and lung cancer treated with ICB. PATIENTS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Histocompatibility Antigens Class I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA Antigens

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Melanoma

Share to Mutation

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 35339648
DOI: 10.1016/j.annonc.2022.03.013
PMCID: PMC10621650

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.PMID 35339648Read ↗

Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance MechanismsSemantic proximity Read ↗

Integrated modeling to implicate evolving neoantigen-T cell interplays and immunotherapy efficacy in tumorsSemantic proximity Read ↗

Integrated germline and somatic features reveal divergent immune pathways driving ICB responseSemantic proximity Read ↗

A novel integrated approach to predicting cancer immunotherapy efficacySemantic proximity Read ↗

HINS: HLA-mediated immunogenic neoantigen score for robust prediction of immune checkpoint blockade responseSemantic proximity Read ↗

Construction and validation of an immunoediting-based optimized neoantigen load (ioTNL) model to predict the response and prognosis of immune checkpoint therapy in various cancers.Semantic proximity Read ↗

Genetic basis for clinical response to CTLA-4 blockade in melanoma.Semantic proximity Read ↗

Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 BlockadeSemantic proximity Read ↗

Is tumor mutational burden predictive of response to immunotherapy?Semantic proximity Read ↗

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.Semantic proximity Read ↗

NeoPrecis: enhancing immunotherapy response prediction through integration of qualified immunogenicity and clonality-aware neoantigen landscapes.Semantic proximity Read ↗

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.